Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391600 | 0.75 | CA1 (0.40) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL23391539 | 0.72 | CYP3A4 (0.41) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL273483 | 0.71 | NR4A1 (0.61) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL23407744 | 0.70 | TTR (0.40) | TSHRMAPK1 | |
| SCHEMBL30838571 | 0.69 | CYP3A4 (0.37) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL23388729 | 0.69 | CYP3A4 (0.37) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL23407747 | 0.67 | THRB (0.37) | CYP3A4TSHRNR4A1ALDH1A1MAPK1 | |
| SCHEMBL23914190 | 0.67 | — | — | |
| SCHEMBL6912094 | 0.66 | THRA (0.45) | TSHRTHRATHRB | |
| SCHEMBL5385598 | 0.65 | THRB (0.49) | ALDH1A1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154216-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES PRODUCED BY MULTIDRUG-RESISTANT BACTERIA | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154216-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES PRODUCED BY MULTIDRUG-RESISTANT BACTERIA | MANBA, MGAM, GUSB | CYP3A4 513/4885TSHR 4181/4885NR4A1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.